Fendiline hydrochloride

1-Cyclohexyl-3′-dodecylurea, is a cell-permeable 1,3-disubstituted urea compound that displays anti-hypertensive and anti-inflammatory properties. 1-Cyclohexyl-3′-dodecylurea acts as a strong, selective, competitive, and tight-binding

1-Cyclohexyl-3′-dodecylurea, is a cell-permeable 1,3-disubstituted urea compound that displays anti-hypertensive and anti-inflammatory properties. 1-Cyclohexyl-3′-dodecylurea acts as a strong, selective, competitive, and tight-binding

1-Cyclohexyl-3′-dodecylurea, is a cell-permeable 1,3-disubstituted urea compound that displays anti-hypertensive and anti-inflammatory properties. 1-Cyclohexyl-3′-dodecylurea acts as a strong, selective, competitive, and tight-binding

A selective &beta1-adrenergic receptor antagonist (log KDs = -8.21, -7.38, and -5.97 for &beta1, &beta2, and &beta3, respectively) used to reduce intraocular pressure in research models of ocular hypertension and glaucoma.

A selective &beta1-adrenergic receptor antagonist (log KDs = -8.21, -7.38, and -5.97 for &beta1, &beta2, and &beta3, respectively) used to reduce intraocular pressure in research models of ocular hypertension and glaucoma.

Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

Biochem/physiol Actions CP-547632 hydrochloride is a well-tolerated, orally-bioavailable ATP-competitive kinase inhibitor. It is currently in clinical trials for the treatment of human malignancies.

Biochem/physiol Actions CP-547632 hydrochloride is a well-tolerated, orally-bioavailable ATP-competitive kinase inhibitor. It is currently in clinical trials for the treatment of human malignancies.